Qiagen Korea presented on Tuesday the clinical trial for QuantiFERON-TB Gold Plus, a diagnostic kit that detects latent tuberculosis in immunocompromised patients.
|Qiagen presenting their clinical trial for QuantiFERON-TB Gold Plus at the Grand Walker Hill Seoul Hotel.|
QuantiFERON-TB Gold Plus is the company’s fourth-generation latency tuberculosis diagnostic kit. It has improved sensitivity from the previous QuantiFERON-TB Gold products, which was equipped with quantitatively measuring the response of CD8+T cells.
“The domestic study on the fourth generation QuantiFERON-TB Gold Plus provides advantages as a clinical marker for diagnosis of latent tuberculosis infection, which can help patients,” said Park Sun-hee 박선희, CEO of Qiagen Korea. “With Korea having the highest incidence of tuberculosis among OCED countries, the company expects the product to detect tuberculosis infection at an earlier stage and lower incidences.”
Qiagen 퀴아젠 is a global bioscience company based in Germany. It provides diagnostic solutions through molecular diagnostics and reagent development.
The company made the presentation during the Laboratory Medicine Congress & Exhibition (LMCE) 2017 and Korean Society for Laboratory Medicine (KSLM) 58th annual meeting, held at the Grand Walker Hill Seoul Hotel.
<© Korea Biomedical Review, All rights reserved.>